| Abstrakt: |
Stroke is characterized by the abrupt failure of blood flow to a specific brain region, resulting in insufficient supply of oxygen and glucose to the ischemic tissues. Timely reperfusion of blood flow can rescue dying tissue but can also lead to secondary damage to both the infarcted tissues and the blood–brain barrier, known as ischemia/reperfusion injury. Both primary and secondary damage result in biphasic opening of the blood–brain barrier, leading to blood–brain barrier dysfunction and vasogenic edema. Importantly, blood–brain barrier dysfunction, inflammation, and microglial activation are critical factors that worsen stroke outcomes. Activated microglia secrete numerous cytokines, chemokines, and inflammatory factors during neuroinflammation, contributing to the second opening of the blood–brain barrier and worsening the outcome of ischemic stroke. TNF-α, IL-1β, IL-6, and other microglia-derived molecules have been shown to be involved in the breakdown of blood–brain barrier. Additionally, other non-microglia-derived molecules such as RNA, HSPs, and transporter proteins also participate in the blood–brain barrier breakdown process after ischemic stroke, either in the primary damage stage directly influencing tight junction proteins and endothelial cells, or in the secondary damage stage participating in the following neuroinflammation. This review summarizes the cellular and molecular components of the blood–brain barrier and concludes the association of microglia-derived and non-microglia-derived molecules with blood–brain barrier dysfunction and its underlying mechanisms. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink